{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:57:06Z","timestamp":1790351826844,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013252","name":"TG Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013252","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jgo.2020.07.007","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T03:52:45Z","timestamp":1594957965000},"page":"256-261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Second primary malignancy among older adults with multiple myeloma receiving first-line lenalidomide-based therapy: A population-based analysis"],"prefix":"10.1016","volume":"12","author":[{"given":"Smith","family":"Giri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Barth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano J.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Olszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgo.2020.07.007_bb0005","author":"National Cancer Institute Surveillance Epidemiology and End Results Program"},{"key":"10.1016\/j.jgo.2020.07.007_bb0010","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jgo.2020.07.007_bb0015","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/cncr.31853","article-title":"Outcomes of secondary solid tumor malignancies among patients with myeloma: a population-based study","volume":"125","author":"Barth","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.jgo.2020.07.007_bb0020","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood-2011-08-373514","article-title":"A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide","volume":"119","author":"Dimopoulos","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2020.07.007_bb0025","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","article-title":"Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data","volume":"15","author":"Palumbo","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jgo.2020.07.007_bb0030","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2020.07.007_bb0035","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/annonc\/mdw606","article-title":"Second primary malignancies in multiple myeloma: an overview and IMWG consensus","volume":"28","author":"Musto","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jgo.2020.07.007_bb0040","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/asheducation-2008.1.359","article-title":"Marginal zone lymphomas: management of nodal, splenic, and MALT NHL","author":"Kahl","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jgo.2020.07.007_bb0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00005650-200208001-00002","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care"},{"key":"10.1016\/j.jgo.2020.07.007_bb0050","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1200\/JCO.2018.77.8894","article-title":"Prescription drug coverage and outcomes of myeloma therapy among medicare beneficiaries","volume":"36","author":"Olszewski","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2020.07.007_bb0055","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2017.72.2447","article-title":"Subsidies for oral chemotherapy and use of immunomodulatory drugs among medicare beneficiaries with myeloma","volume":"35","author":"Olszewski","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2020.07.007_bb0060","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2011-05-355743","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)","volume":"118","author":"Mailankody","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2020.07.007_bb0065","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/bjh.15426","article-title":"Second primary malignancy after multiple myeloma-population trends and cause-specific mortality","volume":"182","author":"Costa","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jgo.2020.07.007_bb0070","doi-asserted-by":"crossref","first-page":"22084","DOI":"10.1038\/srep22084","article-title":"Risk of second primary cancers in multiple myeloma survivors in German and Swedish cancer registries","volume":"6","author":"Chen","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jgo.2020.07.007_bb0075","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3324\/haematol.2015.127548","article-title":"Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 years","volume":"100","author":"Engelhardt","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jgo.2020.07.007_bb0080","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1038\/bcj.2013.19","article-title":"Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics","volume":"3","author":"Razavi","year":"2013","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jgo.2020.07.007_bb0085","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/leu.2013.34","article-title":"Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients","volume":"27","author":"Roeker","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jgo.2020.07.007_bb0090","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood-2011-12-381426","article-title":"Second malignancies after multiple myeloma: from 1960s to 2010s","volume":"119","author":"Thomas","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2020.07.007_bb0095","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.bbmt.2012.09.023","article-title":"Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma","volume":"19","author":"Krishnan","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jgo.2020.07.007_bb0100","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2020.07.007_bb0110","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2020.07.007_bb0115","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2020.07.007_bb0125","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2012.46.3323","article-title":"Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States","volume":"31","author":"Warren","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2020.07.007_bb0130","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2020.07.007_bb0135","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1080\/10428194.2016.1207763","article-title":"Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide","volume":"58","author":"Rollison","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jgo.2020.07.007_bb0140","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.3109\/10428194.2015.1132419","article-title":"Connect MM(R) - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide","volume":"57","author":"Rifkin","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jgo.2020.07.007_bb0145","series-title":"New Malignancies Among Cancer Survivors1973\u20132000","author":"Curtis","year":"2000"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406820301569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406820301569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:52:30Z","timestamp":1761817950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406820301569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1879406820301569"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2020.07.007","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second primary malignancy among older adults with multiple myeloma receiving first-line lenalidomide-based therapy: A population-based analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2020.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}